The diagnostic codes used to identify survey participants with Alzheimer's or other dementias are G30.0, G30.1, G30.8, G30.9, G31.01, G31.09, G31.83, F.01.50, F01.51, F02.80, F02.81, F03.90, F03.91 and F10.27
In the U.S., the FDA has not approved it for medical use and classifies it as a research chemical for scientific studies
CHALLENGES TO DEVELOPMENT In developing the second-generation amylin-analog cagrilintide there were 2 main barriers: (1) to prevent amylin protein aggregation and (2) to extend the amylin-analogs half-life
Systemic copper toxicity from topical application is essentially nonexistent because absorption through intact skin is minimal